<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597335</url>
  </required_header>
  <id_info>
    <org_study_id>P120141</org_study_id>
    <nct_id>NCT02597335</nct_id>
  </id_info>
  <brief_title>Non Invasive Detection of IDH1/2 Mutation in Gliomas</brief_title>
  <acronym>IDASPE</acronym>
  <official_title>Non Invasive IDentification of Gliomas With IDH1/2 Mutation by Analysis of Circulating Plasmatic DNA, D-2-hydroxyglutarate Dosage in Biological Liquids and Detection by Brain SPEctro-MRI: Impact for Diagnosis and Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial develops a non invasive diagnostic approach of IDH1 mutated gliomas combining&#xD;
      mutation detection from free plasmatic DNA, D-2HG dosage in urine samples, and D-2HG&#xD;
      detection by Brain Spectro MRI.&#xD;
&#xD;
      In group 1 (25 patients), patients with presumed grade II-III gliomas candidate to surgery&#xD;
      will undergo spectro MRI, plasma, urine dosages. Results will then be confronted to tumor&#xD;
      mutational status and D-2HG.&#xD;
&#xD;
      In group 2 (15 patients), patients with known IDH1 mutation will undergo spectro MRI, plasma,&#xD;
      urine dosages overtime in order to correlate results with the response to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this trial is to develop and validate a non invasive diagnostic approach of IDH1&#xD;
      mutated gliomas. It will evaluate the specificity and sensitivity of D-2HG detection by Brain&#xD;
      Spectro MRI. This approach will be coupled with mutation detection from free plasmatic DNA&#xD;
      and D-2HG dosage in urine samples.&#xD;
&#xD;
      The primary end-point is the quantification of D-2HG by spectro-MRI, and the correlation with&#xD;
      the dosage of D-2HG in the tumor fragment, and the mutational status (group 1: 25 patients).&#xD;
&#xD;
      The secondary endpoints include:&#xD;
&#xD;
        1. longitudinal analysis Spectro-MRI overtime (12 months) correlation with radiological&#xD;
           evolution and the response to treatment (group 2: 15 patients)&#xD;
&#xD;
        2. Differentiation of tumor recurrence from radiation induced changes&#xD;
&#xD;
        3. Confrontation of Spectro-MRI, D-2HG dosages and IDH mutation detection from plasma DNA,&#xD;
           and elaboration of a combined score of prediction&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>D-2HG quantified by spectroMRI the measure of the ratio between two pics D-2HG and creatine [Time Frame: 3 months after surgery] [Designated as safety issue: No]</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>This ratio D-2HG/creatine will be correlated with the dosage obtained in tumor tissue performed within three months after the surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SpectroMRI [Time Frame: evolution over 12 months] [Designated as safety issue: No]</measure>
    <time_frame>evolution over 12 months</time_frame>
    <description>The ratio D-2HG/creatine will be evaluated overtime and correlated with radiological evolution and the response to treatment (group 2: 15 patients) every four months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioma</condition>
  <condition>IDH1/IDH2 Mutation</condition>
  <arm_group>
    <arm_group_label>IDH1/IDH2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Spectro-MRI</intervention_name>
    <description>Spectro-MRI for D-2HG detection</description>
    <arm_group_label>IDH1/IDH2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dosage of free circulating plasmatic DNA</intervention_name>
    <arm_group_label>IDH1/IDH2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dosage of D-2HG in the urine</intervention_name>
    <arm_group_label>IDH1/IDH2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Affiliation to a social security system&#xD;
&#xD;
          2. Patient≥ 18 years old&#xD;
&#xD;
          3. Written informed consent&#xD;
&#xD;
          4. One of the two situations:&#xD;
&#xD;
               -  presumed grade II-III glioma candidate to surgery (group 1)&#xD;
&#xD;
               -  IDH1/IDH2 mutated grade II-III gliomas, candidate to chemotherapy or radiotherapy&#xD;
                  treatment, or simple follow-up (group 2)&#xD;
&#xD;
          5. Evaluable tumoral mass min diameter &gt;2 cm (FLAIR)&#xD;
&#xD;
          6. PKPS &gt; 60&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Contra-indication to MRI&#xD;
&#xD;
          2. Patient unable to give an written Informed Consent&#xD;
&#xD;
          3. Patient under guardianship or deprived of freedom&#xD;
&#xD;
          4. For group 2: patient already included in group 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Sanson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Sanson, MD, PhD</last_name>
    <phone>+331 42 16 03 91</phone>
    <email>marc.sanson@psl.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Sanson, MD, PhD</last_name>
      <phone>+331 42 16 03 91</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>IDH1/IDH2 mutation</keyword>
  <keyword>Spectroscopy MRI</keyword>
  <keyword>D-2-hydroxyglutarate</keyword>
  <keyword>Free circulating DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

